Single-dose kinetics of intravenous vancomycin

Area of Science:

• Pharmacology
• Clinical Pharmacy
• Drug Metabolism

Background:

• Vancomycin is a critical antibiotic for treating serious Gram-positive infections.
• Understanding vancomycin pharmacokinetics is essential for optimizing therapeutic efficacy and minimizing toxicity.
• Intravenous administration is a common route, necessitating detailed pharmacokinetic profiling.

Purpose of the Study:

• To characterize the pharmacokinetic properties of intravenously administered vancomycin.
• To assess the safety and tolerability of rapid high-dose infusions.
• To determine vancomycin distribution and elimination half-lives in healthy subjects.

Main Methods:

• Intravenous administration of vancomycin in four healthy volunteers.
• Monitoring for adverse effects.
• Analysis of drug concentration over time to determine pharmacokinetic parameters.
• Calculation of distribution and elimination half-lives (t1/2 alpha, t1/2 pi, t1/2 beta).

Main Results:

• Vancomycin distribution followed a biphasic process in all subjects.
• Initial distribution half-life (t1/2 alpha) was under 8 minutes.
• Intermediate half-lives (t1/2 pi) ranged from 0.43 to 1.48 hours.
• Elimination half-lives (t1/2 beta) varied from 4.7 to 11.2 hours.
• Reversible adverse effects (flushing, tachycardia, pruritus) occurred with rapid high-dose infusions.
• Vancomycin clearance was lower than creatinine clearance, attributed to 55% serum protein binding.

Conclusions:

• Intravenous vancomycin exhibits biphasic distribution and a prolonged elimination half-life in healthy individuals.
• Rapid high-dose infusions can lead to transient adverse events.
• Serum protein binding significantly influences vancomycin clearance.
• These pharmacokinetic insights are crucial for guiding vancomycin dosing strategies.